VGG1110E1079 - Common Stock
BIOHAVEN LTD
NYSE:BHVN (11/4/2024, 7:00:00 PM)
After market: 50.04 0 (0%)50.04
-0.84 (-1.65%)
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 239 full-time employees. The company went IPO on 2022-09-23. The firm is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
BIOHAVEN LTD
215 Church Street
New Haven CONNECTICUT 06510
P: 12034040410
CEO: Vlad Coric
Employees: 239
Website: https://www.biohaven.com/
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.
Here you can normally see the latest stock twits on BHVN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: